Clinical trials
Chronic Kidney Disease Requiring Hemodialysis clinical trials
Below are recruiting chronic kidney disease requiring hemodialysis clinical trials, each written for real people, not researchers. We’re tracking 54 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Huntsville, AlabamaAges 18 years+ - NCT06676527Recruiting
Vorolanib for advanced kidney cancer after first treatment
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Nanjing, JiangsuAges 18–80 - NCT06660277Recruiting
Dialysis with expanded solute removal study
This trial tests a special dialysis filter (Elisio HX) that removes more waste products from the blood. It aims to see if this approach improves health outcomes for people on regular in-center hemodialysis.
London, OntarioAges 45 years+ - NCT06635525Recruiting
How kidney failure affects your flu shot response
This study looks at how well the flu vaccine works in people with kidney failure who are on dialysis compared to healthy people. It will help doctors understand how kidney problems affect the body’s immune response to vaccination.
MilanAges 18–70 - NCT06466785RecruitingPhase 3
Study of Efepoetin Alfa for anemia in kidney dialysis patients
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
YerevanAges 18 years+ - NCT06337838RecruitingPhase 3
Preventing blood loss during surgery in kidney patients
This trial tests two medications, tranexamic acid and desmopressin, to see if they can reduce bleeding during surgery in people with severe kidney disease or on dialysis. The results may help make surgery safer for you.
London, OntarioAges 18 years+ - NCT06329622RecruitingPhase 3
Does Ketosteril help muscle loss in kidney disease?
This study tests whether a medicine called Ketosteril can improve muscle strength and function in people with moderate to severe chronic kidney disease (CKD) who also have sarcopenia (age-related muscle loss).
ShanghaiAges Any age - NCT06001827Recruiting
Study of a wrap to help new dialysis access points heal
This trial tests a special wrap placed around a new arm access point for dialysis (called an AV fistula) to see if it helps the access stay healthy and work better. It is for people who need a new AV fistula for kidney dialysis.
Bullhead City, ArizonaAges 18 years+ - NCT05846581Recruiting
Dialysis graft registry for adults getting a new vascular graft
This registry follows adults with kidney failure who need a dialysis access connection in the arm using the GORE ACUSEAL graft. It helps track outcomes and safety over time while you receive standard dialysis care.
BielefeldAges 18 years+ - NCT05828823Recruiting
Two-times-a-week dialysis for new patients
This study tests whether starting dialysis at twice a week, instead of the usual three times, is safe and effective for people who still have some kidney function. If the kidneys still make urine and clear waste, being on dialysis less often may maintain that function longer.
Jacksonville, FloridaAges 18 years+ - NCT05642156Recruiting
Ultrafiltration versus usual dialysis in people on hemodialysis
This study compares a specific way of removing fluid during dialysis (isolated ultrafiltration) with conventional hemodialysis. It aims to see how each approach affects blood flow and fluid shifts in people with end-stage kidney disease.
GrazAges 18 years+ - NCT05465044Recruiting
Twice-weekly dialysis for veterans starting kidney treatment
This study compares starting hemodialysis two times per week versus three times per week for veterans in their first year of dialysis. It aims to see if a less frequent schedule can be just as safe and effective for those who still make urine.
Long Beach, CaliforniaAges 18 years+ - NCT04721652Recruiting
Track drinking and recovery after hemodialysis sessions
This study looks at how fluid intake after each hemodialysis treatment affects your health. It may help find safer, easier guidance on how much to drink between treatments.
London, OntarioAges 18 years+ - NCT04671771Recruiting
Testing a new graft for hemodialysis access in kidney failure
This study tests whether an “AV graft” implant works safely and well for people with end-stage kidney disease who need hemodialysis. It may help your dialysis access last and work better, compared with current expectations for AV grafts.
Phoenix, ArizonaAges 18–90 - NCT03633708RecruitingPhase 3
Etelcalcetide for children with dialysis-related overactive parathyroid hormone
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
Los Angeles, CaliforniaAges birth–18 years - NCT07496177RecruitingPhase 2
HTD1801 for kidney function in diabetes and kidney disease
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
Weifang, ShandongAges 18–75 - NCT07854561RecruitingPhase 2
Romiplostim plus ESAs for dialysis anemia
This trial tests whether adding romiplostim (a medication that helps increase blood cells) to standard ESA therapy can improve anemia in people on dialysis who have not responded well to ESAs alone.
Hong KongAges 18 years+ - NCT05204212Recruiting
Heart procedure to close an atrial clot risk pouch in kidney failure
This trial tests a heart procedure that closes a part of the heart called the left atrial appendage to help prevent stroke in people with an irregular heartbeat (atrial fibrillation) and very advanced kidney disease. It’s mainly for patients who can take the needed blood-thinner medicines and who do not already have a clot in that pouch.
Lübeck, Schleswig-HolsteinAges 18 years+ - NCT04500665RecruitingPhase 2
Colchicine for kidney-related heart inflammation
This Phase 2 trial tests whether colchicine can reduce inflammation and improve heart function in people with kidney disease and a certain type of heart problem. If you qualify, you’ll be closely monitored for side effects and lab changes.
Boston, MassachusettsAges 21–80 - NCT05880914Recruiting
Personalized treatment study for bone disease in kidney failure
This trial looks at a personalized approach to diagnosing and treating bone problems caused by long-term kidney disease. It may help by matching treatment plans to the type of bone turnover found in your tests or biopsy.
St Louis, MissouriAges 18 years+ - NCT06708338Recruiting
Bevel direction during dialysis fistula puncture
This study looks at which way the needle bevel should face when starting dialysis through a new fistula. It might help reduce pain or damage to the fistula.
Le Puy-en-VelayAges 18–85 - NCT06556407Recruiting
Kidney nerve treatment for high blood pressure in dialysis patients
This trial tests a procedure called renal denervation (using radio waves to calm overactive nerves in the kidney) to see if it helps lower blood pressure in people on dialysis who have resistant high blood pressure.
Erlangen, BavariaAges 18–99 - NCT05422534RecruitingPhase 3
CoQ10 plus exercise for people with advanced kidney disease
This trial tests whether a supplement called CoQ10, along with supervised exercise, can improve how the body uses energy in people on chronic dialysis. It may help with muscle function and overall health if your heart and dialysis situation are stable enough.
Sacramento, CaliforniaAges 18–75 - NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Washington D.C., District of ColumbiaAges 4 weeks–18 years
Hear when a new Chronic Kidney Disease Requiring Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic kidney disease requiring hemodialysis?
- Yes. Clin2 currently lists 54 recruiting chronic kidney disease requiring hemodialysis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic kidney disease requiring hemodialysis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic kidney disease requiring hemodialysis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.